Innate Pharma SA: Innate Pharma Highlights Abstracts Selecte

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment

Related Keywords

Chicago , Illinois , United States , Rockville , France , French , American , Pierluigi Porcu , Henry Wheeler , Charu Aggarwal , Olivier Demaria , Arthur Rouill , Lorenzo Falchi , Hirva Mamdani , Astrazeneca , Nasdaq , American Society Of Clinical Oncology , Euronext , Exchange Commission , Linkedin , French Financial Markets Authority , Hoosier Cancer Research Network , Company Annual Report On Form , B Cell Non Hodgkin , Euronext Paris , American Society , Clinical Oncology , Poster Session , Hematologic Malignancies Lymphoma , Chronic Lymphocytic Leukemia , Monday June , Multicenter Trial Investigating , Preliminary Antineoplastic Activity , Patients With Relapsed , Non Hodgkin Lymphoma , Lung Cancer Non Small Cell , Engager Therapeutics , Innate Pharma , Private Securities Litigation Reform Act , Risk Factors , Universal Registration Document , Annual Report , Ihr Portfolio ,